Scientific Resources

hero-background-image
A Human-Relevant <i>Ex Vivo</i> IBD Model for Therapeutic Development and Preclinical Testing (2).png

https://website-content.rouken.bio/insights_d48a5b481e.svgInsights

|

4 September 2026

|

7 min read

Advancing Asthma Drug Discovery and Translational Research with a Human Air-Liquid Interface (ALI) Asthma Model

RoukenBio’s human donor-derived air-liquid interface (ALI) asthma model recreates key features of Type 2 airway inflammation, including mucus production and epithelial remodelling. Discover how this translational platform supports target validation, biomarker analysis and therapeutic evaluation in asthma drug discovery.

202608 - Development of a high-throughput multimodal patient-derived platform integrating autologous fibroblasts and tumour-infiltrating lymphocytes for colorectal cancer drug discovery .png

https://website-content.rouken.bio/research_poster_039a1b785f.svgResearch Posters

|

17 August 2026

|

4 min read

Development of a high-throughput multimodal patient-derived platform integrating autologous fibroblasts and tumourinfiltrating lymphocytes for colorectal cancer drug discovery

This research poster presents a high-throughput, patient-derived colorectal cancer tumoroid platform incorporating autologous fibroblasts and tumour-infiltrating lymphocytes. By combining genomic, gene-expression and drug-response data, the model captures patient-specific tumour heterogeneity and supports translational drug discovery, predictive biomarker identification and immunotherapy research.

Blog image - A Human-Relevant <i>Ex Vivo</i> IBD Model for Therapeutic Development and Preclinical Testing.png

https://website-content.rouken.bio/insights_d48a5b481e.svgInsights

|

5 August 2026

|

5 min read

A Human-Relevant Ex Vivo IBD Model for Therapeutic Development and Preclinical Testing

Explore how RoukenBio’s patient-derived ex vivo IBD model preserves key tissue compartments to support more clinically relevant therapeutic testing for Crohn’s disease and ulcerative colitis.

Luke Checkpoint Blockade

https://website-content.rouken.bio/insights_d48a5b481e.svgInsights

|

22 July 2026

|

5 min read

From Exhausted T Cells to Durable Responses: Checkpoint Blockade, the Next Wave of Targets, and Why We Still Revisit Barber et al. (2006)

Immune checkpoint blockade has transformed immuno-oncology by turning T cell biology into a powerful therapeutic strategy. This article explores how checkpoint science continues to evolve, from PD-1/PD-L1 therapies to next-generation targets, and why revisiting landmark studies like Barber et al. (2006) remains valuable for linking immune mechanisms to functional outcomes.

Join our community of curious minds on LinkedIn

🗓️ Stay informed with our monthly scientific newsletter, published on LinkedIn on the last Wednesday of each month.

These editions bring you the latest in drug development breakthroughs, industry trends, and expert insights from the brilliant minds at RoukenBio.

Subscribe today on LinkedIn

Propel drug discovery breakthroughs with RoukenBio

Difficulty doesn’t deter us; it inspires us. Give us a problem, and we’ll find your solution. Our versatile specialists embrace every obstacle as an opportunity to showcase our innovative thinking and problem-solving prowess.

RoukenBio - Capabilities brochure.pngcta-image